Randomized within-subject trial to evaluate smokers’ initial perceptions, subjective effects and nicotine delivery across six vaporized nicotine products

Addiction

Volumn 114, Issue 7, 2019, Pages 1236-1248

  Voos, Natalie ^a   Kaiser, Lisa ^a   Mahoney, Martin C ^a   Bradizza, Clara M ^b   Kozlowski, Lynn T ^c   Benowitz, Neal L ^d   O'Connor, Richard J ^a   Goniewicz, Maciej L ^a  

^a Roswell Park Comprehensive Cancer Center   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

e cigarettes; electronic cigarettes; electronic delivery systems; nicotine; vaping; vaporizers

Indexed keywords

NICOTINE; NICOTINIC AGENT;

ADULT; ATTITUDE; CIGARETTE SMOKING; CROSSOVER PROCEDURE; ELECTRONIC CIGARETTE; FEMALE; HUMAN; MALE; MIDDLE AGED; RANDOMIZATION; SATISFACTION; SMOKING; TOBACCO DEPENDENCE; VAPING;

ADULT; ATTITUDE; CIGARETTE SMOKING; CROSS-OVER STUDIES; ELECTRONIC NICOTINE DELIVERY SYSTEMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINE; NICOTINIC AGONISTS; PERSONAL SATISFACTION; RANDOM ALLOCATION; SMOKERS; TOBACCO USE DISORDER; VAPING;

EID: 85065047785     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.14602     Document Type: Article

References (44)

1. Polosa R., Rodu B., Caponnetto P., Maglia M., Raciti C. A fresh look at tobacco harm reduction: the case for the electronic cigarette. Harm Reduct J 2013; 10: 19.
2. Hajek P. Electronic cigarettes for smoking cessation. Lancet 2013; 382: 1614–1616.
3. Sweanor D., Alcabes P., Drucker E. Tobacco harm reduction: how rational public policy could transform a pandemic. Atlanta, GA: Elsevier; 2007.
4. Laverty A. A., Filippidis F. T., Vardavas C. I. Patterns, trends and determinants of e-cigarette use in 28 European Union Member States 2014–2017. Prev Med 2018; 116: 13–18.
5. Bao W., Xu G., Lu J., Snetselaar L. G., Wallace R. B. Changes in electronic cigarette use among adults in the United States, 2014–2016. JAMA 2018; 319: 2039–2041.
6. Wang T. W., Asman K., Gentzke A. S., Cullen K. A., Holder-Hayes E., Reyes-Guzman C. et al. Tobacco product use among adults—United States, 2017. Morb Mortal Wkly Rep 2018; 67: 1225–1232.
7. Phillips E., Wang T. W., Husten C. G., Corey C. G., Apelberg B. J., Jamal A. et al. Tobacco product use among adults—United States, 2015. Morb Mortal Wkly Rep 2017; 66: 1209.
8. Kozlowski L. T., Homish D. L., Homish G. G. Daily users compared to less frequent users find vape as or more satisfying and less dangerous than cigarettes, and are likelier to use non-cig-alike vaping products. Prev Med Rep 2017; 6: 111–114.
9. Goniewicz M. L., Knysak J., Gawron M., Kosmider L., Sobczak A., Kurek J. et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob Control 2014; 23: 133–139.
10. National Academies of Sciences, Engineering and Medicine. Public Health Consequences of e-Cigarettes, Vol. 10. Washington, DC: National Academies Press; 2018, p. 24952.
11. Shahab L., Goniewicz M. L., Blount B. C., Brown J., McNeill A., Alwis K. U. et al. Nicotine, carcinogen, and toxin exposure in long-term E-cigarette and nicotine replacement therapy users: a cross-sectional study. Ann Intern Med 2017; 166: 390–400.
12. Goniewicz M. L., Gawron M., Smith D. M., Peng M., Jacob P., Benowitz N. L. Exposure to nicotine and selected toxicants in cigarette smokers who switched to electronic cigarettes: a longitudinal within-subjects observational study. Nicotine Tob Res 2017; 19: 160–167.
13. Hecht S. S., Carmella S. G., Kotandeniya D., Pillsbury M. E., Chen M., Ransom B. W. et al. Evaluation of toxicant and carcinogen metabolites in the urine of e-cigarette users versus cigarette smokers. Nicotine Tob Res 2014; 17: 704–709.
14. Hitchman S. C., Brose L. S., Brown J., Robson D., McNeill A. Associations between e-cigarette type, frequency of use, and quitting smoking: findings from a longitudinal online panel survey in Great Britain. Nicotine Tob Res 2015; 17: 1187–1194.
15. Wagener T. L., Floyd E. L., Stepanov I., Driskill L. M., Frank S. G., Meier E. et al. Have combustible cigarettes met their match? The nicotine delivery profiles and harmful constituent exposures of second-generation and third-generation electronic cigarette users. Tob Control 2017; 26: e23–e28.
16. St Helen G., Havel C., Dempsey D. A., Jacob P., Benowitz N. L. Nicotine delivery, retention and pharmacokinetics from various electronic cigarettes. Addiction 2016; 111: 535–544.
17. Dawkins L., Kimber C., Puwanesarasa Y., Soar K. First- versus second-generation electronic cigarettes: predictors of choice and effects on urge to smoke and withdrawal symptoms. Addiction 2015; 110: 669–677.
18. Hajek P., Przulj D., Phillips A., Anderson R., McRobbie H. Nicotine delivery to users from cigarettes and from different types of e-cigarettes. Psychopharmacology (Berl) 20; 234: 773–779.
19. O'Connor R. J., Fix B. V., Goniewicz M. L., Travers M. B., Heckman B. W., Cummings K. M. et al. Characteristics of vaporized nicotine products used by participants in the ITC Four Country Tobacco and E-Cigarette Project, wave 1. Addiction 2019; https://doi.org/10.1111/add.14571.
20. Berry K. M., Reynolds L. M., Collins J. M., Siegel M. B., Fetterman J. L., Hamburg N. M. et al. E-cigarette initiation and associated changes in smoking cessation and reduction: the Population Assessment of Tobacco and Health Study, 2013–2015. Tob Control 2018; https://doi.org/10.1136/tobaccocontrol-2017-054108.
21. Heatherton T. F., Kozlowski L. T., Frecker R. C., Fagerstrom K. O. The Fagerström Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991; 86: 1119–1127.
22. Goniewicz M. L., Kuma T., Gawron M., Knysak J., Kosmider L. Nicotine levels in electronic cigarettes. Nicotine Tob Res 2013; 15: 158–166.
23. Wang B.-S., Wang X.-J., Gong L.-K. The construction of a Williams design and randomization in cross-over clinical trials using SAS. J Stat Softw 2009; 29: 1–10.
24. Jacob P. III, Yu L., Wilson M., Benowitz N. L. Selected ion monitoring method for determination of nicotine, cotinine and deuterium-labeled analogs: absence of an isotope effect in the clearance of (S)-nicotine-3′, 3′-d2 in humans. Biol Mass Spectrom 1991; 20: 247–252.
25. Helen G. S., Shahid M., Chu S., Benowitz N. L. Impact of e-liquid flavors on e-cigarette vaping behavior. Drug Alcohol Depend 2018; 189: –48.
26. Benowitz N. L., Hukkanen J., Jacob P. Nicotine chemistry, metabolism, kinetics and biomarkers. Handbk Exp Psychopharmacol 2009; 192: 29–60.
27. Allen G. D. MODFIT: a pharmacokinetics computer program. Biopharm Drug Dispos 1990; 11: 477–498.
28. Hughes J. R., Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 1986; 43: 289–294.
29. Etter J. F., Hughes J. R. A comparison of the psychometric properties of three cigarette withdrawal scales. Addiction 2006; 101: 362–372.
30. Cox L. S., Tiffany S. T., Christen A. G. Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine Tob Res 2001; 3: 7–16.
31. Morean M. E., de Wit H., King A. C., Sofuoglu M., Rueger S. Y., O'Malley S. S. The drug effects questionnaire: psychometric support across three drug types. Psychopharmacology (Berl) 2013; 227: 177–192.
32. Hatsukami D. K., Zhang Y., O'Connor R. J., Severson H. H. Subjective responses to oral tobacco products: scale validation. Nicotine Tob Res 2012; 15: 1259–1264.
33. Benowitz N. L., Jacob P., Herrera B. Nicotine intake and dose response when smoking reduced-nicotine content cigarettes. Clin Pharmacol Ther 2006; 80: 703–714.
34. Chen S.-Y., Feng Z., Yi X. A general introduction to adjustment for multiple comparisons. J Thorac Dis 2017; 9: 1725–1729.
35. Richardson A., Pearson J., Xiao H., Stalgaitis C., Vallone D. Prevalence, harm perceptions, and reasons for using noncombustible tobacco products among current and former smokers. Am J Public Health 2014; 104: 1437–1444.
36. Kalkhoran S., Alvarado N., Vijayaraghavan M., Lum P. J., Yuan P., Satterfield J. M. Patterns of and reasons for electronic cigarette use in primary care patients. J Gen Intern Med 2017; 32: 1122–1129.
37. Notley C., Ward E., Dawkins L., Holland R. The unique contribution of e-cigarettes for tobacco harm reduction in supporting smoking relapse prevention. Harm Reduct J 201; 15: 31.
38. Pearson J. L., Richardson A., Niaura R. S., Vallone D. M., Abrams D. B. e-Cigarette awareness, use, and harm perceptions in US adults. Am J Public Health 2012; 102: 1758–1766.
39. Li Q., Zhan Y., Wang L., Leischow S. J., Zeng D. D. Analysis of symptoms and their potential associations with e-liquids’ components: a social media study. BMC Public Health 2016; 16: 674.
40. Barbeau A. M., Burda J., Siegel M. Perceived efficacy of e-cigarettes versus nicotine replacement therapy among successful e-cigarette users: a qualitative approach. Addict Sci Clin Pract 2013; 8: 5.
41. Kralikova E., Novak J., West O., Kmetova A., Hajek P. Do e-cigarettes have the potential to compete with conventional cigarettes? A survey of conventional cigarette smokers’ experiences with e-cigarettes. Chest 2013; 144: 1609–1614.
42. JUUL Labs Inc. Patents, Trademarks, Copyrights: JUUL Labs, Inc. 2018. Available at: https://www.juul.com/intellectual-property-list (accessed 20 December 2018) (Archived at http://www.webcitation.org/75hDdg6ky on 20 December 2018).
43. Soule E. K., Lopez A. A., Guy M. C., Cobb C. O. Reasons for using flavored liquids among electronic cigarette users: a concept mapping study. Drug Alcohol Depend 2016; 166: 168–176.
44. Litt M. D., Duffy V., Oncken C. Cigarette smoking and electronic cigarette vaping patterns as a function of e-cigarette flavourings. Tob Control 2016; https://doi.org/10.1136/tobaccocontrol-2016-053223.